Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORMAT: Fibrinogen Concentrate for Refractory Bleeding in Hematological Patients
NCT05091684Phase 2Terminated
- Sponsor
- CHU Saint-Etienne
- Start
- Feb 2022
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fibrinogen human in hemorrhage and Thrombocytopenia, sponsored by CHU Saint-Etienne. Primary endpoint: Maximal clot elasticity (viscoelastic test of clotting function) at 3 hours. Started Feb 2022; status: terminated.
02
Drugs
Fibrinogen human
03
Conditions
hemorrhageThrombocytopenia
Beyond the preview
Go deeper on NCT05091684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05091684.